High expression levels of macrophage migration inhibitory factor sustain the innate immune responses of neonates

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 8, 2016, Pages E997-E1005

  Roger, Thierry ^a   Schneider, Anina ^a   Weier, Manuela ^a   Sweep, Fred C G J ^b   Roy, Didier Le ^a   Bernhagen, Jörgen ^c,d,e   Calandra, Thierry ^a   Giannoni, Eric ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RWTH AACHEN UNIVERSITY   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e Technische Universität München Munich Cluster for Systems Neurology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; MACROPHAGE MIGRATION INHIBITION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROSTAGLANDIN; ISOMERASE; MIF PROTEIN, HUMAN; MIF PROTEIN, MOUSE; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ESCHERICHIA COLI; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; INFECTION SENSITIVITY; INNATE IMMUNITY; NEWBORN SEPSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STREPTOCOCCUS AGALACTIAE; ADULT; ANIMAL; FEMALE; GENE EXPRESSION REGULATION; IMMUNOLOGY; MALE; MONOCYTE; MOUSE; NEWBORN; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ADULT; ANIMALS; ESCHERICHIA COLI; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; INFANT, NEWBORN; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MONOCYTES; STREPTOCOCCUS AGALACTIAE;

EID: 84959450073     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1514018113     Document Type: Article

References (79)

1. Stoll BJ, et al.; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network (2011) Early onset neonatal sepsis: The burden of group B Streptococcal and E. coli disease continues. Pediatrics 127(5): 817-826.
2. Giannoni E, et al.; Swiss Pediatric Sepsis Study Group (2016) Incidence and outcome of group B streptococcal sepsis in infants in Switzerland. Pediatr Infect Dis J 35(2):222-224.
3. Levy O (2007) Innate immunity of the newborn: Basic mechanisms and clinical correlates. Nat Rev Immunol 7(5):379-390.
4. Kollmann TR, et al. (2009) Neonatal innate TLR-mediated responses are distinct from those of adults. J Immunol 183(11):7150-7160.
5. Aksoy E, et al. (2007) Interferon regulatory factor 3-dependent responses to lipopolysaccharide are selectively blunted in cord blood cells. Blood 109(7):2887-2893.
6. Belderbos ME, et al. (2009) Skewed pattern of Toll-like receptor 4-mediated cytokine production in human neonatal blood: Low LPS-induced IL-12p70 and high IL-10 persist throughout the first month of life. Clin Immunol 133(2):228-237.
7. Pettengill MA, van Haren SD, Levy O (2014) Soluble mediators regulating immunity in early life. Front Immunol 5:457.
8. Levy O, et al. (2004) Selective impairment of TLR-mediated innate immunity in human newborns: Neonatal blood plasma reduces monocyte TNF-Alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848. J Immunol 173(7):4627-4634.
9. Levy O, et al. (2006) The adenosine system selectively inhibits TLR-mediated TNF-Alpha production in the human newborn. J Immunol 177(3):1956-1966.
10. Giannoni E, et al. (2011) Estradiol and progesterone strongly inhibit the innate immune response of mononuclear cells in newborns. Infect Immun 79(7):2690-2698.
11. Kauppila A, Koivisto M, Pukka M, Tuimala R (1978) Umbilical cord and neonatal cortisol levels. Effect of gestational and neonatal factors. Obstet Gynecol 52(6):666-672.
12. Mitchell MD, Lucas A, Etches PC, Brunt JD, Turnbull AC (1978) Plasma prostaglandin levels during early neonatal life following term and pre-Term delivery. Prostaglandins 16(2):319-326.
13. Belderbos ME, Levy O, Meyaard L, Bont L (2013) Plasma-mediated immune suppression: A neonatal perspective. Pediatr Allergy Immunol 24(2):102-113.
14. Gomez R, et al. (1998) The fetal inflammatory response syndrome. Am J Obstet Gynecol 179(1):194-202.
15. Calandra T, Roger T (2003) Macrophage migration inhibitory factor: A regulator of innate immunity. Nat Rev Immunol 3(10):791-800.
16. Leng L, et al. (2003) MIF signal transduction initiated by binding to CD74. J Exp Med 197(11):1467-1476.
17. Bernhagen J, et al. (2007) MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 13(5):587-596.
18. Hudson JD, et al. (1999) A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 190(10):1375-1382.
19. Kleemann R, et al. (2000) Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 408(6809):211-216.
20. Filip AM, et al. (2009) Ribosomal protein S19 interacts with macrophage migration inhibitory factor and attenuates its pro-inflammatory function. J Biol Chem 284(12): 7977-7985.
21. Roger T, Chanson AL, Knaup-Reymond M, Calandra T (2005) Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoidinduced expression of mitogen-Activated protein kinase phosphatase-1. Eur J Immunol 35(12):3405-3413.
22. Roger T, Froidevaux C, Martin C, Calandra T (2003) Macrophage migration inhibitory factor (MIF) regulates host responses to endotoxin through modulation of Toll-like receptor 4 (TLR4). J Endotoxin Res 9(2):119-123.
23. Calandra T, et al. (2000) Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6(2):164-170.
24. Lehmann LE, et al. (2001) Plasma levels of macrophage migration inhibitory factor are elevated in patients with severe sepsis. Intensive Care Med 27(8):1412-1415.
25. Bozza FA, et al. (2004) Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 22(4):309-313.
26. Emonts M, et al. (2007) Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis. Clin Infect Dis 44(10):1321-1328.
27. Calandra T, et al. (1995) MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377(6544):68-71.
28. Kevill KA, et al. (2008) A role for macrophage migration inhibitory factor in the neonatal respiratory distress syndrome. J Immunol 180(1):601-608.
29. Calandra T, Bernhagen J, Mitchell RA, Bucala R (1994) The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 179(6):1895-1902.
30. Roger T, Ding X, Chanson AL, Renner P, Calandra T (2007) Regulation of constitutive and microbial pathogen-induced human macrophage migration inhibitory factor (MIF) gene expression. Eur J Immunol 37(12):3509-3521.
31. Flieger O, et al. (2003) Regulated secretion of macrophage migration inhibitory factor is mediated by a non-classical pathway involving an ABC transporter. FEBS Lett 551(1-3):78-86.
32. Lubetsky JB, et al. (2002) The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem 277(28):24976-24982.
33. Wennekamp J, Henneke P (2008) Induction and termination of inflammatory signaling in group B streptococcal sepsis. Immunol Rev 225:114-127.
34. Takeuchi O, Akira S (2010) Pattern recognition receptors and inflammation. Cell 140(6):805-820.
35. Roger T, David J, Glauser MP, Calandra T (2001) MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 414(6866):920-924.
36. Mitchell RA, Metz CN, Peng T, Bucala R (1999) Sustained mitogen-Activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem 274(25):18100-18106.
37. Roger T, et al. (2013) Macrophage migration inhibitory factor deficiency is associated with impaired killing of gram-negative bacteria by macrophages and increased susceptibility to Klebsiella pneumoniae sepsis. J Infect Dis 207(2):331-339.
38. Aeberli D, et al. (2006) Endogenous macrophage migration inhibitory factor modulates glucocorticoid sensitivity in macrophages via effects on MAP kinase phosphatase-1 and p38 MAP kinase. FEBS Lett 580(3):974-981.
39. Martin L, Pingle SC, Hallam DM, Rybak LP, Ramkumar V (2006) Activation of the adenosine A3 receptor in RAW264.7 cells inhibits lipopolysaccharide-stimulated tumor necrosis factor-Alpha release by reducing calcium-dependent activation of nuclear factor-kappaB and extracellular signal-regulated kinase 1/2. J Pharmacol Exp Ther 316(1):71-78.
40. Beishuizen A, Thijs LG, Haanen C, Vermes I (2001) Macrophage migration inhibitory factor and hypothalamo-pituitary-Adrenal function during critical illness. J Clin Endocrinol Metab 86(6):2811-2816.
41. Bernhagen J, et al. (1993) MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365(6448):756-759.
42. Calandra T, Spiegel LA, Metz CN, Bucala R (1998) Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Grampositive bacteria. Proc Natl Acad Sci USA 95(19):11383-11388.
43. Al-Abed Y, et al. (2005) ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem 280(44): 36541-36544.
44. Al-Abed Y, et al. (2011) Thyroxine is a potential endogenous antagonist of macrophage migration inhibitory factor (MIF) activity. Proc Natl Acad Sci USA 108(20):8224-8227.
45. Kerschbaumer RJ, et al. (2012) Neutralization of macrophage migration inhibitory factor (MIF) by fully human antibodies correlates with their specificity for the β-sheet structure of MIF. J Biol Chem 287(10):7446-7455.
46. Irestedt L, Dahlin I, Hertzberg T, Sollevi A, Lagercrantz H (1989) Adenosine concentration in umbilical cord blood of newborn infants after vaginal delivery and cesarean section. Pediatr Res 26(2):106-108.
47. Petrovsky N, et al. (2003) Macrophage migration inhibitory factor exhibits a pronounced circadian rhythm relevant to its role as a glucocorticoid counter-regulator. Immunol Cell Biol 81(2):137-143.
48. Leng L, et al. (2009) Glucocorticoid-induced MIF expression by human CEM T cells. Cytokine 48(3):177-185.
49. Bacher M, et al. (1996) An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 93(15):7849-7854.
50. Lehmann LE, et al. (2008) Oxidoreductase Macrophage Migration Inhibitory Factor is simultaneously increased in leukocyte subsets of patients with severe sepsis. Biofactors 33(4):281-291.
51. Ströbmann T, et al. (2013) Platelets are a previously unrecognised source of MIF. Thromb Haemost 110(5):1004-1013.
52. Rossi AG, et al. (1998) Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF). Potential role in asthma. J Clin Invest 101(12):2869-2874.
53. Sabat R, et al. (2010) Biology of interleukin-10. Cytokine Growth Factor Rev 21(5):331-344.
54. Rutz S, Wang X, Ouyang W (2014) The IL-20 subfamily of cytokines-From host defence to tissue homeostasis. Nat Rev Immunol 14(12):783-795.
55. Bosmann M, Ward PA (2013) Modulation of inflammation by interleukin-27. J Leukoc Biol 94(6):1159-1165.
56. Lue H, et al. (2006) Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal 18(5):688-703.
57. Lue H, Dewor M, Leng L, Bucala R, Bernhagen J (2011) Activation of the JNK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on CXCR4 and CD74. Cell Signal 23(1):135-144.
58. Toh ML, et al. (2006) Regulation of IL-1 and TNF receptor expression and function by endogenous macrophage migration inhibitory factor. J Immunol 177(7):4818-4825.
59. Belderbos ME, et al. (2012) Neonatal plasma polarizes TLR4-mediated cytokine responses towards low IL-12p70 and high IL-10 production via distinct factors. PLoS One 7(3):e33419.
60. Huh SY, et al. (2008) Association between umbilical cord glucocorticoids and blood pressure at age 3 years. BMC Med 6:25.
61. Medeiros A, Peres-Buzalaf C, Fortino Verdan F, Serezani CH (2012) Prostaglandin E2 and the suppression of phagocyte innate immune responses in different organs. Mediators Inflamm 2012:327568.
62. Dooper MM, Wassink L, M'Rabet L, Graus YM (2002) The modulatory effects of prostaglandin-E on cytokine production by human peripheral blood mononuclear cells are independent of the prostaglandin subtype. Immunology 107(1):152-159.
63. Serezani CH, Ballinger MN, Aronoff DM, Peters-Golden M (2008) Cyclic AMP: Master regulator of innate immune cell function. Am J Respir Cell Mol Biol 39(2):127-132.
64. Power Coombs MR, Belderbos ME, Gallington LC, Bont L, Levy O (2011) Adenosine modulates Toll-like receptor function: Basic mechanisms and translational opportunities. Expert Rev Anti Infect Ther 9(2):261-269.
65. Ramakers BP, Riksen NP, van der Hoeven JG, Smits P, Pickkers P (2011) Modulation of innate immunity by adenosine receptor stimulation. Shock 36(3):208-215.
66. Lavoie PM, et al. (2010) Profound lack of interleukin (IL)-12/IL-23p40 in neonates born early in gestation is associated with an increased risk of sepsis. J Infect Dis 202(11):1754-1763.
67. Azizia M, Lloyd J, Allen M, Klein N, Peebles D (2012) Immune status in very preterm neonates. Pediatrics 129(4):e967-e974.
68. Wynn JL, Wong HR (2010) Pathophysiology and treatment of septic shock in neonates. Clin Perinatol 37(2):439-479.
69. Zhao J, et al. (2008) Hyper innate responses in neonates lead to increased morbidity and mortality after infection. Proc Natl Acad Sci USA 105(21):7528-7533.
70. Schlapbach LJ, et al. (2013) Pancreatic stone protein as a novel marker for neonatal sepsis. Intensive Care Med 39(4):754-763.
71. Krow-Lucal ER, Kim CC, Burt TD, McCune JM (2014) Distinct functional programming of human fetal and adult monocytes. Blood 123(12):1897-1904.
72. Gibbons D, et al. (2014) Interleukin-8 (CXCL8) production is a signatory T cell effector function of human newborn infants. Nat Med 20(10):1206-1210.
73. Elahi S, et al. (2013) Immunosuppressive CD71+ erythroid cells compromise neonatal host defence against infection. Nature 504(7478):158-162.
74. Dimova T, et al. (2015) Effector Vγ9Vδ2 T cells dominate the human fetal γδ T-cell repertoire. Proc Natl Acad Sci USA 112(6):E556-E565.
75. Zhang X, et al. (2014) CD4 T cells with effector memory phenotype and function develop in the sterile environment of the fetus. Sci Transl Med 6(238):238ra72.
76. Radstake TR, et al. (2005) Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum 52(10):3020-3029.
77. Mischke R, et al. (1997) Structure activity studies of the cytokine macrophage migration inhibitory factor (MIF) reveal a critical role for its carboxy terminus. FEBS Lett 414(2):226-232.
78. Delaloye J, et al. (2009) Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog 5(6):e1000480.
79. Lugrin J, et al. (2009) Histone deacetylase inhibitors repress macrophage migration inhibitory factor (MIF) expression by targeting MIF gene transcription through a local chromatin deacetylation. Biochim Biophys Acta 1793(11):1749-1758.